• Explore /
  • Poster
  • / A phase II randomized trial of talimogene laherparepvec (T-VEC) oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.

A phase II randomized trial of talimogene laherparepvec (T-VEC) oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.

Abstract Poster

Authors

null

Christopher A. Barker

Memorial Sloan Kettering Cancer Center, New York, NY

Christopher A. Barker , Sandra P. D'Angelo , Alexa M. Steckler , Ming Lian , Gloria Wasilewski , Mario E. Lacouture , Paul B. Chapman , Alexander Noor Shoushtari , Charlotte Eielson Ariyan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Other IO-Related Topics

Clinical Trial Registration Number

NCT02819843

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2639)

DOI

10.1200/JCO.2023.41.16_suppl.2639

Abstract #

2639

Poster Bd #

481

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Phase 2 study of pembrolizumab plus lenvatinib and belzutifan in patients with metastatic esophageal squamous cell carcinoma.

Phase 2 study of pembrolizumab plus lenvatinib and belzutifan in patients with metastatic esophageal squamous cell carcinoma.

First Author: Carlos Rojas

First Author: Hewitt Chang

First Author: Brian Gastman

First Author: Justine Yang Bruce